Redox Biology and Immune Response in SARS-CoV-2 Infection

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Francesco Bellanti	+ 1701 word(s)	1701	2022-01-26 07:44:15	\|
2	format correct	Catherine Yang	-2 word(s)	1699	2022-03-03 02:39:22	\|

This entry is adapted from the peer-reviewed paper 10.3390/biology11020159

Reactive species and redox imbalance may dysregulate the immune response and account for disease progression in SARS-CoV-2 infection. This aspect suggests treatment options that could hinder disease progression and prevent multiple features of severe illness, which include clotting predisposition, cytokine storm and organ damage.

COVID-19 immune response redox biology

1. COVID-19, Redox Balance and Immunity

1.1. COVID-19 Is Characterized by Impaired Redox Homeostasis

Due to its crucial role in response to infections, oxidative stress is considered a key determinant in COVID-19 pathogenesis ^[1]^[2]. Pathological changes underlying pulmonary damage induced by SARS-CoV-2 include exudative proteinaceous injury and inflammatory lymphocytic infiltrates, diffuse alveolar damage with hyaline membranes and wall thickening ^[3]. Severe COVID-19 is further characterized by hypercoagulation and hypoxia in several organs ^[4]. Such massive induction of tissue damage can be related to a defective redox balance ^[5].

Excess of reactive species and consequent dysregulated redox homeostasis were described in several respiratory viral infections. Following activation of innate immunity and pro-inflammatory cytokines, infection by respiratory syncytial virus induces overproduction of reactive species, increasing lipid peroxidation, depleting GSH and inhibiting NRF2 in respiratory epithelial cells ^[6]^[7]. Influenza virus leads to reactive species excess in several tissues, particularly in lungs, inducing apoptosis and cytotoxicity, but activating NRF2 to counteract oxidative injury in alveolar epithelial cells ^[8]^[9]^[10]. Several pre-clinical studies suggest that severe lung damage in SARS-CoV infection relies on both oxidative stress and innate immunity, with consequent activation of NF-κB and enhanced pro-inflammatory host response ^[11]^[12]^[13]. In convalescent patients, an upregulation of mitochondrial and redox-sensitive genes occurs, supporting the association between redox imbalance, inflammation and the pathogenesis of SARS-CoV infection ^[14].

According to previous evidence from similar viral infections, impairment in redox balance may deeply impact COVID-19 pathogenesis, even though reports sustaining this hypothesis are still limited. Several radical scavengers, such as GSH, NADPH or Trx, may regulate the cellular disulfide–thiol balance, which is crucial for SARS-CoV-2 entry and fusion into the host cell ^[1]. Deficiency of G6PD may be associated with severe COVID-19, since redox homeostasis mediated by this enzyme is involved in the immune response to viral infections ^[15]. This is strongly suggested by the following evidence: (1) G6PD deficiency enhances several viral infections; (2) G6PD variants may impact COVID-19 severity; and (3) higher incidence of COVID-19 in African-Americans, whose G6PD deficiency is characterized by higher oxidative stress ^[16]^[17]^[18]^[19]. A pilot study on COVID-19 patients hospitalized in intensive care unit showed reduced circulating levels of several antioxidants (such as vitamin C, thiol proteins, GSH, γ-tocopherol, β-carotene), as well increased lipid peroxides and the oxidative stress index copper/zinc ratio ^[20]. When the total oxidant status, total antioxidant capacity and level of glutathione were compared in hospitalized COVID-19 patients with different disease severity, increased oxidative stress indices and reduced antioxidant markers were related to serious clinical presentation and outcomes ^[21]. Nevertheless, another study showed no correlation observed between the oxidative stress parameters and the degree of COVID-19 severity in hospitalized patients, suggesting that disease severity may not contribute to redox changes in SARS-CoV-2 infection ^[22]. A preliminary report on a small sample of critically ill COVID-19 patients described higher levels of protein adducts of the lipid peroxidation product 4-hydroxynonenal in the deceased, as compared to survivors ^[23]. Compared to healthy controls, circulating SOD and CAT activity, as well as carbonyl and lipid peroxidation (LPO) levels, were higher, while total antioxidant capacity levels were lower in COVID-19 patients ^[23]. Moreover, higher LPO levels were independently associated with a higher risk of intubation or death at 28 days ^[23]. A further study demonstrated that neutrophils are the main source of reactive species in severe COVID-19, and circulating H₂O₂ levels are increased in dead patients ^[24].

1.2. Altered Redox Balance Modulates the Immune Response

Redox biology accomplishes key regulatory functions in innate immunity. Increased production of reactive species by phagocytes is one of the first-line antimicrobial responses, defined as the oxidative/respiratory burst ^[25]. More than merely producing reactive species via NADPH oxidase, neutrophils may sense the differential localization of oxidants and finely tune IL-1β expression through selective oxidation of NF-κB ^[26]. Mitochondria-derived reactive species further regulate the differentiation process of dendritic cells ^[27]. Furthermore, mitochondrial reactive species in macrophages enter the cytosol and induce a covalent modification in NF-κB essential modulator (NEMO), an element of the inhibitor of κB kinase (IKK) complex required to activate both the ERK1/2 and NF-κB pathways and to promote secretion of pro-inflammatory cytokines ^[28]. Reactive species are also produced by NADPH oxidase in natural killer T cells (but not in CD4+ or CD8+ T cells), modulating their expression of IFN-γ and IL-17, thus playing a role in the regulation of inflammatory function ^[29].

Redox signaling and regulation are crucial in adaptive immunity. Indeed, excessive production of reactive species is associated with the activation and differentiation of both T and B cells. T helper activation, required for both humoral and cell-mediated immune response, relies on the redox status of the microenvironment ^[30]. Even though a reduced microenvironment could protect from oxidative stress during T cell activation, mild concentrations of reactive species are necessary for the initiation of adaptive immune response ^[31]. Activation of CD28, costimulatory of T cell activation, induces intracellular reactive species, with consequent induction of IL-2 via NF-κB ^[32]. On the other hand, the antioxidant GSH is required to regulate the proliferation of activated T cells ^[33]. Nevertheless, low amounts of reactive species are a precondition for T cell survival, while oxidant accumulation causes apoptosis/necrosis ^[34]. Moreover, redox signaling may affect T cell commitment, and different T cells present with various redox levels ^[34]. Indeed, oxidative status induces Th1 development, while prevalence of reducing molecules shifts toward Th2 responses ^[35].

2. Targeting Impaired Redox Homeostasis in COVID-19

Several studies suggest that redox balance may be a feasible therapeutic target for COVID-19 by modulating the redox-sensitive immune response. Numerous trials have been designed to test antioxidants (such as N-acetylcysteine, ascorbic acid, resveratrol) in COVID-19, and many of them are currently ongoing while this review is being written.

N-acetylcysteine (NAC) could potentially treat COVID-19 infection by stimulating glutathione synthesis, promoting T cell response and regulating inflammation ^[36]. Other than providing an extra source of cysteine to synthetize glutathione, NAC can stop ACE2 activity and SARS-CoV-2 entry into target cells by the presence of a thiol group ^[37]. NAC was intravenously administered in patients with severe COVID-19, contributing to clinical improvement, as well as reduction of C-reactive protein ^[38]. A retrospective two-center cohort study showed that oral NAC reduces the risk of mechanical ventilation and mortality when added to standard of care in patients with moderate to severe COVID-19 ^[39]. However, a double-blind randomized trial was not able to demonstrate that intravenous administration of NAC in high doses was superior to placebo in affecting the evolution of severe COVID-19 ^[40]. Similar results were observed in a pilot study, which could not support beneficial effects of intravenous NAC in COVID-19 patients with acute respiratory distress syndrome ^[41].

Ascorbic acid (vitamin C) is a potent antioxidant, which directly scavenges reactive species, and it is also highly concentrated in leukocytes for several immune responses ^[42]^[43]. The first suggestion on the efficacy of vitamin C in reducing susceptibility to respiratory tract infections derives from Linus Pauling ^[44]. Circulating levels of ascorbic acid were severely depleted in COVID-19 patients with acute respiratory distress syndrome ^[45]. Administration of high-dose intravenous vitamin C was associated with improved inflammatory and immune response, as well as restored organ function in severe/critical COVID-19 ^[46]. Nevertheless, a pilot study failed to demonstrate any clinical improvement in critically ill COVID-19 patients treated with intravenous high doses of ascorbic acid ^[47]. Two randomized controlled trials could not demonstrate that the addition of intravenous vitamin C to standard therapy had an impact on mortality, length of stay or the need for mechanical ventilation in COVID-19 patients ^[48]^[49].

Resveratrol is a polyphenol with several antioxidant, anti-inflammatory and immunomodulator properties ^[50]. More than being a simple scavenger of reactive species, resveratrol increases the expression of the antioxidant protein SIRT1, which in turn boosts NAD levels, improving the immune response ^[51]. Resveratrol has been demonstrated to reduce the replication of SARS-CoV-2 in vitro, showing antiviral properties in infected human bronchial epithelial cells ^[52]^[53]. In a placebo-controlled cross-over study, resveratrol supplementation in obese men reduced the expression of ACE2 in adipose tissue, suggesting that this compound could reduce SARS-CoV-2 diffusion ^[54]. A randomized placebo-controlled phase 2 trial showed that oral supplementation of resveratrol in COVID-19 outpatients presented with lower incidence of pneumonia and hospitalization ^[55].

Pharmacological activation of the transcriptional factor NRF2 has been recently suggested as a promising therapeutic strategy against COVID-19 due to restoration of redox homeostasis and resolution of inflammation ^[56]. Sulforaphane is an electrophile that modifies cysteine sensors of Keap1, inactivating its repressor functions ^[57]. This compound is able to inhibit the replication of SARS-CoV-2 in vitro and in the upper respiratory tract or lungs of SARS-CoV-2-infected mice, reducing pulmonary injury ^[58]. Furthermore, sulforaphane inhibits the expression of IL-6 and IL-8 in cultured bronchial cells exposed to the S-protein of SARS-CoV-2, supporting its anti-inflammatory effect ^[59]. Nevertheless, no clinical data on the efficacy of sulforaphane are currently available. Bardoxolone and bardoxolone methyl are electrophilic moieties able to activate the NRF2 pathway and inhibit the NF-κB pathway ^[60]. Both compounds can inhibit SARS-CoV-2 replication by specifically binding the 3C-like protease in infected Vero cells ^[61]. Hence, even these Nrf2 activators may be considered in a multifaceted antiviral treatment strategy.

Other compounds involved in the interplay with redox homeostasis were suggested to be potentially beneficial in the treatment of COVID-19. Polyphenols are natural agents with high antioxidant and anti-inflammatory properties, which could also target virus proteins or cell receptors, preventing SARS-CoV-2 entry and replication ^[62]. Acting as anti-inflammatory and antioxidant, the bioactive molecule melatonin may be effective in reducing acute lung injury caused by SARS-CoV-2 ^[63]. The trace element zinc—whose deficiency is reported in severe COVID-19—may prevent SARS-CoV-2 by improving respiratory tissue barrier and inhibiting viral replication, but also balancing immune response and redox homeostasis ^[64]. The novel antifibrotic agent pirfenidone could reduce inflammation and counteract oxidative stress, antagonizing apoptosis and downregulating ACE2 expression ^[65]. Selenium is another trace element incorporated in several selenoproteins with both anti-inflammatory and antioxidant functions; the expression of several selenoproteins is decreased by SARS-CoV-2 infection, and redox-active selenium molecules might potentially inhibit SARS-CoV-2 proteases. All these redox compounds can be considered as promising in counteracting SARS-CoV-2 infection and modulating an immune response to COVID-19, even though further studies are needed.

References

Chernyak, B.V.; Popova, E.N.; Prikhodko, A.S.; Grebenchikov, O.A.; Zinovkina, L.A.; Zinovkin, R.A. COVID-19 and Oxidative Stress. Biochemistry 2020, 85, 1543–1553.
Carpenito, L.; D’Ercole, M.; Porta, F.; Di, B.E.; Doi, P.; Fagara, G.R.; Rey, R.; Bulfamante, G. The autopsy at the time of SARS-CoV-2: Protocol and lessons. Ann. Diagn. Pathol. 2020, 48, 151562.
Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020, 8, 420–422.
Cecchini, R.; Cecchini, A.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med. Hypotheses 2020, 143, 110102.
Casola, A.; Burger, N.; Liu, T.; Jamaluddin, M.; Brasier, A.R.; Garofalo, R.P. Oxidant tone regulates RANTES gene expression in airway epithelial cells infected with respiratory syncytial virus. Role in viral-induced interferon regulatory factor activation. J. Biol. Chem. 2001, 276, 19715–19722.
Hosakote, Y.M.; Jantzi, P.D.; Esham, D.L.; Spratt, H.; Kurosky, A.; Casola, A.; Garofalo, R.P. Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. Am. J. Respir Crit. Care Med. 2011, 183, 1550–1560.
Kosmider, B.; Messier, E.M.; Janssen, W.J.; Nahreini, P.; Wang, J.; Hartshorn, K.L.; Mason, R.J. Nrf2 protects human alveolar epithelial cells against injury induced by influenza A virus. Respir Res. 2012, 13, 43.
Selemidis, S.; Seow, H.J.; Broughton, B.R.; Vinh, A.; Bozinovski, S.; Sobey, C.G.; Drummond, G.R.; Vlahos, R. Nox1 oxidase suppresses influenza a virus-induced lung inflammation and oxidative stress. PLoS ONE 2013, 8, e60792.
Amatore, D.; Sgarbanti, R.; Aquilano, K.; Baldelli, S.; Limongi, D.; Civitelli, L.; Nencioni, L.; Garaci, E.; Ciriolo, M.R.; Palamara, A.T. Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS. Cell Microbiol. 2015, 17, 131–145.
Padhan, K.; Minakshi, R.; Towheed, M.A.B.; Jameel, S. Severe acute respiratory syndrome coronavirus 3a protein activates the mitochondrial death pathway through p38 MAP kinase activation. J. Gen. Virol. 2008, 89, 1960–1969.
van den Brand, J.M.; Haagmans, B.L.; Osterhaus, A.D.; Kuiken, T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J. Comp. Pathol. 2014, 151, 83–112.
Fung, T.S.; Liu, D.X. Human Coronavirus: Host-Pathogen Interaction. Annu. Rev. Microbiol. 2019, 73, 529–557.
Shao, H.; Lan, D.; Duan, Z.; Liu, Z.; Min, J.; Zhang, L.; Huang, J.; Su, J.; Chen, S.; Xu, A. Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. J. Clin. Immunol. 2006, 26, 546–554.
Wu, Y.H.; Tseng, C.P.; Cheng, M.L.; Ho, H.Y.; Shih, S.R.; Chiu, D.T. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J. Infect. Dis. 2008, 197, 812–816.
Yang, H.C.; Ma, T.H.; Tjong, W.Y.; Stern, A.; Chiu, D.T. G6PD deficiency, redox homeostasis, and viral infections: Implications for SARS-CoV-2 (COVID-19). Free Radic. Res. 2021, 55, 364–374.
Ho, H.Y.; Cheng, M.L.; Weng, S.F.; Chang, L.; Yeh, T.T.; Shih, S.R.; Chiu, D.T. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J. Gen. Virol. 2008, 89, 2080–2089.
Elhabyan, A.; Elyaacoub, S.; Sanad, E.; Abukhadra, A.; Elhabyan, A.; Dinu, V. The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review. Virus Res. 2020, 289, 198163.
Andrasfay, T.; Goldman, N. Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations. Proc. Natl. Acad. Sci. USA 2021, 118, e2014746118.
Pincemail, J.; Cavalier, E.; Charlier, C.; Cheramy-Bien, J.P.; Brevers, E.; Courtois, A.; Fadeur, M.; Meziane, S.; Goff, C.L.; Misset, B.; et al. Oxidative Stress Status in COVID-19 Patients Hospitalized in Intensive Care Unit for Severe Pneumonia. A Pilot Study. Antioxidants 2021, 10, 257.
Karkhanei, B.; Talebi, G.E.; Mehri, F. Evaluation of oxidative stress level: Total antioxidant capacity, total oxidant status and glutathione activity in patients with COVID-19. New Microbes New Infect. 2021, 42, 100897.
Gadotti, A.C.; Lipinski, A.L.; Vasconcellos, F.T.; Marqueze, L.F.; Cunha, E.B.; Campos, A.C.; Oliveira, C.F.; Amaral, A.N.; Baena, C.P.; Telles, J.P.; et al. Susceptibility of the patients infected with SARS-CoV2 to oxidative stress and possible interplay with severity of the disease. Free Radic. Biol. Med. 2021, 165, 184–190.
Zarkovic, N.; Orehovec, B.; Milkovic, L.; Barsic, B.; Tatzber, F.; Wonisch, W.; Tarle, M.; Kmet, M.; Mataic, A.; Jakovcevic, A.; et al. Preliminary Findings on the Association of the Lipid Peroxidation Product 4-Hydroxynonenal with the Lethal Outcome of Aggressive COVID-19. Antioxidants 2021, 10, 1341.
Martin-Fernandez, M.; Aller, R.; Heredia-Rodriguez, M.; Gomez-Sanchez, E.; Martinez-Paz, P.; Gonzalo-Benito, H.; Sanchez-de, P.L.; Gorgojo, O.; Carnicero-Frutos, I.; Tamayo, E.; et al. Lipid peroxidation as a hallmark of severity in COVID-19 patients. Redox Biol. 2021, 48, 102181.
Babior, B.M. Oxidants from phagocytes: Agents of defense and destruction. Blood 1984, 64, 959–966.
Warnatsch, A.; Tsourouktsoglou, T.D.; Branzk, N.; Wang, Q.; Reincke, S.; Herbst, S.; Gutierrez, M.; Papayannopoulos, V. Reactive Oxygen Species Localization Programs Inflammation to Clear Microbes of Different Size. Immunity 2017, 46, 421–432.
Del Prete, A.; Zaccagnino, P.; Di, P.M.; Saltarella, M.; Oliveros, C.C.; Nico, B.; Santoro, G.; Lorusso, M. Role of mitochondria and reactive oxygen species in dendritic cell differentiation and functions. Free Radic. Biol. Med. 2008, 44, 1443–1451.
Herb, M.; Gluschko, A.; Wiegmann, K.; Farid, A.; Wolf, A.; Utermohlen, O.; Krut, O.; Kronke, M.; Schramm, M. Mitochondrial reactive oxygen species enable proinflammatory signaling through disulfide linkage of NEMO. Sci. Signal. 2019, 12, eaar5926.
Kim, Y.H.; Kumar, A.; Chang, C.H.; Pyaram, K. Reactive Oxygen Species Regulate the Inflammatory Function of NKT Cells through Promyelocytic Leukemia Zinc Finger. J. Immunol. 2017, 199, 3478–3487.
Yan, Z.; Garg, S.K.; Kipnis, J.; Banerjee, R. Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 2009, 5, 721–723.
Matsue, H.; Edelbaum, D.; Shalhevet, D.; Mizumoto, N.; Yang, C.; Mummert, M.E.; Oeda, J.; Masayasu, H.; Takashima, A. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J. Immunol. 2003, 171, 3010–3018.
Los, M.; Schenk, H.; Hexel, K.; Baeuerle, P.A.; Droge, W.; Schulze-Osthoff, K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 1995, 14, 3731–3740.
Suthanthiran, M.; Anderson, M.E.; Sharma, V.K.; Meister, A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc. Natl. Acad Sci. USA 1990, 87, 3343–3347.
Kesarwani, P.; Murali, A.K.; Al-Khami, A.A.; Mehrotra, S. Redox regulation of T-cell function: From molecular mechanisms to significance in human health and disease. Antioxid. Redox Signal. 2013, 18, 1497–1534.
Peterson, J.D.; Herzenberg, L.A.; Vasquez, K.; Waltenbaugh, C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc. Natl. Acad. Sci. USA 1998, 95, 3071–3076.
Poe, F.L.; Corn, J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med. Hypotheses 2020, 143, 109862.
De, F.S.; Balansky, R.; La, M.S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020, 34, 13185–13193.
Ibrahim, H.; Perl, A.; Smith, D.; Lewis, T.; Kon, Z.; Goldenberg, R.; Yarta, K.; Staniloae, C.; Williams, M. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin. Immunol. 2020, 219, 108544.
Assimakopoulos, S.F.; Aretha, D.; Komninos, D.; Dimitropoulou, D.; Lagadinou, M.; Leonidou, L.; Oikonomou, I.; Mouzaki, A.; Marangos, M. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: A two-center retrospective cohort study. Infect. Dis. 2021, 53, 847–854.
de Alencar, J.C.G.; Moreira, C.L.; Muller, A.D.; Chaves, C.E.; Fukuhara, M.A.; da Silva, E.A.; Miyamoto, M.F.S.; Pinto, V.B.; Bueno, C.G.; Lazar, N.F.; et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin. Infect. Dis. 2021, 72, e736–e741.
Taher, A.; Lashgari, M.; Sedighi, L.; Rahimi-Bashar, F.; Poorolajal, J.; Mehrpooya, M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol. Rep. 2021, 73, 1650–1659.
Carr, A.C.; Shaw, G.M.; Fowler, A.A.; Natarajan, R. Ascorbate-dependent vasopressor synthesis: A rationale for vitamin C administration in severe sepsis and septic shock? Crit. Care 2015, 19, 418.
Koekkoek, W.A.; van Zanten, A.R. Antioxidant Vitamins and Trace Elements in Critical Illness. Nutr. Clin. Pract. 2016, 31, 457–474.
Pauling, L. Ascorbic acid and the common cold. Am. J. Clin. Nutr. 1971, 24, 1294–1299.
Chiscano-Camon, L.; Ruiz-Rodriguez, J.C.; Ruiz-Sanmartin, A.; Roca, O.; Ferrer, R. Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome. Crit. Care 2020, 24, 522.
Zhao, B.; Ling, Y.; Li, J.; Peng, Y.; Huang, J.; Wang, Y.; Qu, H.; Gao, Y.; Li, Y.; Hu, B.; et al. Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: A retrospective case series study. Ann. Palliat Med. 2021, 10, 1599–1609.
Zhang, J.; Rao, X.; Li, Y.; Zhu, Y.; Liu, F.; Guo, G.; Luo, G.; Meng, Z.; De, B.D.; Xiang, H.; et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann. Intensive Care 2021, 11, 5.
Kumari, P.; Dembra, S.; Dembra, P.; Bhawna, F.; Gul, A.; Ali, B.; Sohail, H.; Kumar, B.; Memon, M.K.; Rizwan, A. The Role of Vitamin C as Adjuvant Therapy in COVID-19. Cureus 2020, 12, e11779.
JamaliMoghadamSiahkali, S.; Zarezade, B.; Koolaji, S.; SeyedAlinaghi, S.; Zendehdel, A.; Tabarestani, M.; Sekhavati, M.E.; Abbasian, L.; Dehghan Manshadi, S.A.; Salehi, M.; et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: A randomized open-label clinical trial. Eur. J. Med. Res. 2021, 26, 20.
Malaguarnera, L. Influence of Resveratrol on the Immune Response. Nutrients 2019, 11, 946.
Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K.; Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003, 309, 1017–1026.
Pasquereau, S.; Nehme, Z.; Haidar, A.S.; Daouad, F.; Van, A.J.; Wallet, C.; Schwartz, C.; Rohr, O.; Morot-Bizot, S.; Herbein, G. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses 2021, 13, 354.
ter Ellen, B.M.; Dinesh Kumar, N.; Bouma, E.M.; Troost, B.; van de Pol, D.P.I.; van der Ende-Metselaar, H.H.; Apperloo, L.; van Gosliga, D.; van den Berge, M.; Nawijn, M.C.; et al. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air–Liquid Interface Cultured Human Primary Bronchial Epithelial Cells. Viruses 2021, 13, 1335.
de Ligt, M.; Hesselink, M.K.C.; Jorgensen, J.; Hoebers, N.; Blaak, E.E.; Goossens, G.H. Resveratrol supplementation reduces ACE2 expression in human adipose tissue. Adipocyte 2021, 10, 408–411.
McCreary, M.R.; Schnell, P.M.; Rhoda, D.A. Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19). Res. Sq. 2021, rs.3, rs-861831.
Cuadrado, A.; Pajares, M.; Benito, C.; Jimenez-Villegas, J.; Escoll, M.; Fernandez-Gines, R.; Garcia Yague, A.J.; Lastra, D.; Manda, G.; Rojo, A.I.; et al. Can Activation of NRF2 Be a Strategy against COVID-19? Trends Pharmacol. Sci. 2020, 41, 598–610.
Ahmed, S.M.; Luo, L.; Namani, A.; Wang, X.J.; Tang, X. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta. Mol. Basis Dis. 2017, 1863, 585–597.
Ordonez, A.A.; Bullen, C.K.; Villabona-Rueda, A.F.; Thompson, E.A.; Turner, M.L.; Davis, S.L.; Komm, O.; Powell, J.D.; D’Alessio, F.R.; Yolken, R.H.; et al. Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses. bioRxiv 2021.
Gasparello, J.; d’Aversa, E.; Papi, C.; Gambari, L.; Grigolo, B.; Borgatti, M.; Finotti, A.; Gambari, R. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. Phytomedicine 2021, 87, 153583.
Del Prete, D.; Taglialatela-Scafati, O.; Minassi, A.; Sirignano, C.; Cruz, C.; Bellido, M.L.; Munoz, E.; Appendino, G. Electrophilic Triterpenoid Enones: A Comparative Thiol-Trapping and Bioactivity Study. J. Nat. Prod. 2017, 80, 2276–2283.
Sun, Q.; Ye, F.; Liang, H.; Liu, H.; Li, C.; Lu, R.; Huang, B.; Zhao, L.; Tan, W.; Lai, L. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct. Target Ther. 2021, 6, 212.
El-Missiry, M.A.; Fekri, A.; Kesar, L.A.; Othman, A.I. Polyphenols are potential nutritional adjuvants for targeting COVID-19. Phytother. Res. 2021, 35, 2879–2889.
Zhang, R.; Wang, X.; Ni, L.; Di, X.; Ma, B.; Niu, S.; Liu, C.; Reiter, R.J. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020, 250, 117583.
Wessels, I.; Rolles, B.; Rink, L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front. Immunol. 2020, 11, 1712.
Seifirad, S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med. Hypotheses 2020, 144, 110005.
Zhang, J.; Saad, R.; Taylor, E.W.; Rayman, M.P. Selenium and selenoproteins in viral infection with potential relevance to COVID-19. Redox Biol. 2020, 37, 101715.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Immunology

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Francesco Bellanti

View Times: 649

Update Date: 03 Mar 2022

Table of Contents

Video Upload Options

Confirm